Delivery Order SPE2DB24D3013-SPE2DB26FFFQL
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Dapagliflozin 10 mg tablets (30-count units) valued at $15,245.22 under a firm fixed price arrangement. This competitively awarded, non-set-aside delivery order is scheduled for completion by August 27, 2025, with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract represents a continuation of the company's role as a critical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dapagliflozin 10 mg tablets (30-count) with a ceiling value of $5,275.63. This competitive, non-set-aside delivery order represents a firm fixed price transaction with an ultimate completion date of July 29, 2025. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 15, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with a ceiling value of $7,808.87 and an ultimate completion date of October 16, 2025. The contract carries no set-aside designation, indicating it was competitively awarded. Performance of this delivery will occur at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dapagliflozin 10 mg tablets in a 30-count package at a ceiling value of $1,333.77. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 21, 2025. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units, with a ceiling value of $5,358.11 and a firm fixed price structure. The contract represents a non-set-aside, competitively awarded delivery order with an ultimate completion date of July 25, 2025. This award is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30, with a contract ceiling value of $4,380.23 and an ultimate completion date of August 11, 2025. This competitive, non-set-aside delivery order utilizes firm fixed price terms and represents a continuation of the federal pharmaceutical supply relationship between DLA and the prime contractor. The place of performance is...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30, with a contract ceiling value of $5,097.35. This is a firm fixed-price delivery order with an ultimate completion date of September 10, 2025, and represents a non-set-aside competitive award. The delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units, with a ceiling value of $11,089.97. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is scheduled for ultimate completion on September 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units, with a ceiling value of $28,970.38. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 5, 2025, and represents a component of the company's broader pharmaceutical supply relationship with the federal government. The work will be performed at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 10, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units. This competitively awarded, non-set-aside contract carries a ceiling value of $1,472.58 with firm fixed pricing and an ultimate completion date of July 11, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB26FFFQLDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on October 17, 2025, for the supply of Dapagliflozin 10 mg tablets (30-count) with a ceiling value of $3.5K. This is a firm fixed-price delivery order with an ultimate completion date of October 20, 2025, and carries no set-aside designation, indicating it was competitively awarded. The product will be supplied to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1B vehicle valued through December 2026 that provides comprehensive pharmaceutical and medical supply support to military healthcare systems globally. AmerisourceBergen's federal contract portfolio demonstrates extensive experience supplying critical medications across multiple therapeutic domains to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The award reflects the company's continued role as a primary pharmaceutical vendor supporting federal medical procurement requirements within DLA's Medical Supply Chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.5k | 10/17/25 |